Xpovio

Active Ingredient(s): Selinexor
FDA Approved: * July 3, 2019
Pharm Company: * KARYOPHARM THERAPEUTICS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xpovio Overview

Selinexor (INN, trade name Xpovio; development code KPT-330) is a selective inhibitor of nuclear export used as an anti-cancer drug. It works by binding to exportin 1 and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis.[1] It is the first drug with this mechanism of action.[2][3] Selinexor was granted accelerated ...

Read more Xpovio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Selinexor

Recent Xpovio Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Xpovio: (1 result)

Sorted by National Drug Code

• 72237-101 Xpovio 20 mg Oral Tablet, Film Coated by Karyopharm Therapeutics Inc.

Other drugs which contain Selinexor or a similar ingredient: (1 result)

• SELINEXOR